Synlogic (SYBX) Competitors $1.48 +0.03 (+2.07%) As of 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock SYBX vs. ATRA, VNRX, CNTX, IRD, OTLK, CUE, ZIVO, IZTC, APLT, and ICCCShould you be buying Synlogic stock or one of its competitors? The main competitors of Synlogic include Atara Biotherapeutics (ATRA), VolitionRx (VNRX), Context Therapeutics (CNTX), Opus Genetics (IRD), Oncobiologics (OTLK), Cue Biopharma (CUE), ZIVO Bioscience (ZIVO), Invizyne Technologies (IZTC), Applied Therapeutics (APLT), and ImmuCell (ICCC). These companies are all part of the "pharmaceutical products" industry. Synlogic vs. Its Competitors Atara Biotherapeutics VolitionRx Context Therapeutics Opus Genetics Oncobiologics Cue Biopharma ZIVO Bioscience Invizyne Technologies Applied Therapeutics ImmuCell Atara Biotherapeutics (NASDAQ:ATRA) and Synlogic (NASDAQ:SYBX) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, valuation, profitability, analyst recommendations, dividends, media sentiment, institutional ownership and risk. Which has better valuation and earnings, ATRA or SYBX? Synlogic has lower revenue, but higher earnings than Atara Biotherapeutics. Atara Biotherapeutics is trading at a lower price-to-earnings ratio than Synlogic, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAtara Biotherapeutics$128.94M0.67-$85.40M-$0.43-28.58Synlogic$10K1,731.60-$23.36M-$2.51-0.59 Which has more volatility and risk, ATRA or SYBX? Atara Biotherapeutics has a beta of 0.26, suggesting that its stock price is 74% less volatile than the S&P 500. Comparatively, Synlogic has a beta of 0.52, suggesting that its stock price is 48% less volatile than the S&P 500. Do insiders & institutionals hold more shares of ATRA or SYBX? 70.9% of Atara Biotherapeutics shares are owned by institutional investors. Comparatively, 63.4% of Synlogic shares are owned by institutional investors. 4.0% of Atara Biotherapeutics shares are owned by insiders. Comparatively, 3.0% of Synlogic shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media favor ATRA or SYBX? In the previous week, Atara Biotherapeutics had 5 more articles in the media than Synlogic. MarketBeat recorded 7 mentions for Atara Biotherapeutics and 2 mentions for Synlogic. Atara Biotherapeutics' average media sentiment score of 1.04 beat Synlogic's score of 0.43 indicating that Atara Biotherapeutics is being referred to more favorably in the media. Company Overall Sentiment Atara Biotherapeutics Positive Synlogic Neutral Do analysts prefer ATRA or SYBX? Atara Biotherapeutics currently has a consensus target price of $20.00, suggesting a potential upside of 62.73%. Given Atara Biotherapeutics' stronger consensus rating and higher probable upside, equities research analysts clearly believe Atara Biotherapeutics is more favorable than Synlogic.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Atara Biotherapeutics 0 Sell rating(s) 2 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.83Synlogic 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Is ATRA or SYBX more profitable? Atara Biotherapeutics has a net margin of 3.07% compared to Synlogic's net margin of 0.00%. Synlogic's return on equity of -8.09% beat Atara Biotherapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Atara Biotherapeutics3.07% -8.34% 6.61% Synlogic N/A -8.09%-5.50% SummaryAtara Biotherapeutics beats Synlogic on 12 of the 17 factors compared between the two stocks. Get Synlogic News Delivered to You Automatically Sign up to receive the latest news and ratings for SYBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SYBX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SYBX vs. The Competition Export to ExcelMetricSynlogicMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$16.96M$3.11B$5.63B$9.83BDividend YieldN/A2.23%3.79%4.08%P/E Ratio-0.597.0921.9023.75Price / Sales1,731.60367.51465.67116.64Price / CashN/A42.3037.4059.05Price / Book1.378.659.096.18Net Income-$23.36M-$54.65M$3.25B$264.89M7 Day Performance5.71%6.59%4.76%2.66%1 Month Performance12.12%9.57%6.72%3.05%1 Year Performance4.23%14.06%30.51%25.05% Synlogic Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SYBXSynlogic0.9606 of 5 stars$1.48+2.1%N/A+2.8%$16.96M$10K-0.5980Short Interest ↑Gap UpATRAAtara Biotherapeutics4.6287 of 5 stars$10.32-5.8%$20.00+93.8%+51.8%$65.31M$128.94M-2.77330Positive NewsEarnings ReportVNRXVolitionRx2.1979 of 5 stars$0.63-2.6%$3.50+460.0%+16.5%$64.99M$1.31M-1.7480News CoverageAnalyst ForecastGap UpCNTXContext Therapeutics3.5292 of 5 stars$0.68-5.9%$5.25+675.3%-71.7%$64.57MN/A-1.887Short Interest ↓Gap UpIRDOpus Genetics1.8673 of 5 stars$1.06-0.9%$7.33+591.8%N/A$63.84M$10.99M-0.5014News CoverageEarnings ReportOTLKOncobiologics1.8168 of 5 stars$1.96+3.2%$9.60+389.8%-66.9%$63.78MN/A-2.1520News CoverageEarnings ReportAnalyst ForecastGap UpCUECue Biopharma4.5113 of 5 stars$0.83+0.0%$4.00+381.1%+27.4%$62.62M$9.29M-1.2460Earnings ReportGap UpZIVOZIVO Bioscience0.2582 of 5 stars$16.21+11.9%N/A+112.4%$61.87M$15.85K-3.3210News CoverageGap UpIZTCInvizyne TechnologiesN/A$9.84-1.7%N/AN/A$61.52MN/A0.0029Gap DownAPLTApplied Therapeutics4.466 of 5 stars$0.45+5.5%$6.10+1,258.3%-92.0%$60.26M$460K-1.0430News CoverageEarnings ReportShort Interest ↓Gap DownICCCImmuCell0.4072 of 5 stars$6.66flatN/A+90.9%$60.19M$26.49M-95.1370News CoverageEarnings ReportShort Interest ↓ Related Companies and Tools Related Companies Atara Biotherapeutics Competitors VolitionRx Competitors Context Therapeutics Competitors Opus Genetics Competitors Oncobiologics Competitors Cue Biopharma Competitors ZIVO Bioscience Competitors Invizyne Technologies Competitors Applied Therapeutics Competitors ImmuCell Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SYBX) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Synlogic, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Synlogic With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access